Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Heron Therapeutics (HRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 822,453
  • Shares Outstanding, K 53,580
  • Annual Sales, $ 1,280 K
  • Annual Income, $ -173,140 K
  • 36-Month Beta 1.51
  • Price/Sales 638.79
  • Price/Cash Flow 0.00
  • Price/Book 0.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.30 +15.41%
on 04/06/17
15.90 -3.46%
on 04/19/17
+0.40 (+2.68%)
since 03/28/17
3-Month
12.25 +25.31%
on 01/30/17
15.90 -3.46%
on 04/19/17
+2.90 (+23.29%)
since 01/27/17
52-Week
12.21 +25.72%
on 01/12/17
24.00 -36.04%
on 08/10/16
-6.26 (-28.97%)
since 04/28/16

Most Recent Stories

More News
Heron Therapeutics Appoints Robert E. Hoffman as Chief Financial Officer and Senior Vice President, Finance

Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on developing novel best-in-class treatments to address some of the biggest unmet patient needs, announced...

HRTX : 15.35 (unch)
Overcoming Opioids: The quest for less addictive drugs

Tummy tucks really hurt. Doctors carve from hip to hip, slicing off skin, tightening muscles, tugging at innards. Patients often need strong painkillers for days or even weeks, but Mary Hernandez went...

PFE : 33.92 (+0.18%)
HRTX : 15.35 (unch)
Heron Therapeutics to Present at the 16th Annual Needham Healthcare Conference

Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on developing novel best-in-class treatment solutions to address some of the biggest unmet patient...

HRTX : 15.35 (unch)
How These Drug Makers Stocks are Faring? -- Sanofi, Impax Laboratories, Heron Therapeutics, and GW Pharma

Ahead of today's trading session, Stock-Callers.com shifts focus on four major players in the Drug Manufacturers space: Sanofi SA (NYSE: SNY), Impax Laboratories Inc. (NASDAQ: IPXL), Heron Therapeutics...

IPXL : 14.05 (+1.81%)
GWPH : 118.73 (+0.25%)
SNY : 47.30 (+0.83%)
HRTX : 15.35 (unch)
Heron Therapeutics to Present at the 37th Annual Cowen and Company Healthcare Conference

Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on developing novel best-in-class treatment solutions to address some of the biggest unmet patient...

HRTX : 15.35 (unch)
LifeSci Capital Initiates Coverage of Heron Therapeutics

Developing Enhanced Versions of Approved Products Using the Proprietary Biochronomer™ Polymer-Based Drug Delivery Technology

HRTX : 15.35 (unch)
Heron Announces Submission of CINVANTI(TM) NDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)

Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on developing novel best-in-class treatment solutions to address some of the biggest unmet patient...

HRTX : 15.35 (unch)
Heron Therapeutics Announces Positive Topline Results From Phase 2 Clinical Trial of HTX-011 in Abdominoplasty

--- Results confirm broad utility of HTX-011 with successful use across wide range of surgeries, from small to very large incisions -

HRTX : 15.35 (unch)
Heron Therapeutics Establishes Synergy of Bupivacaine and Meloxicam with HTX-011 for Prevention of Post-Operative Pain in Phase 2 Clinical Studies

--- Conference call and webcast at 8:30 a.m. ET on January 5, 2017 -

HRTX : 15.35 (unch)
Susan G. Komen(R) Joins Forces With Heron Therapeutics to Raise Awareness of the Supportive Care Needs of Patients With Breast Cancer

Susan G. Komen and Heron Therapeutics, Inc. today announced that the two organizations have joined forces to encourage supporters to take action in the fight against breast...

HRTX : 15.35 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting....

See More

Support & Resistance

2nd Resistance Point 15.95
1st Resistance Point 15.65
Last Price 15.35
1st Support Level 15.05
2nd Support Level 14.75

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.